Two Sigma Investments’s Avadel Pharmaceuticals AVDL Stock Holding History

Two Sigma Investments’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-71,336	Closed	-$1.54M	–	4580
2025 Q4	$1.54M	Buy	+71,336	New	+$1.38M	﹤0.01%	2637
2024 Q2	–	Sell	-62,609	Closed	-$1.06M	–	3021
2024 Q1	$1.06M	Sell	62,609 -11,991	-16%	-$179K	﹤0.01%	1925
2023 Q4	$1.05M	Hold	74,600	–	–	﹤0.01%	2044
2023 Q3	$768K	Sell	74,600 -254,204	-77%	-$3.4M	﹤0.01%	2074
2023 Q2	$5.42M	Buy	328,804 +219,243	+200%	+$2.85M	0.01%	889
2023 Q1	$1M	Sell	109,561 -9,460	-8%	-$77.8K	﹤0.01%	1860
2022 Q4	$852K	Sell	119,021 -105,943	-47%	-$743K	﹤0.01%	1778
2022 Q3	$1.13M	Sell	224,964 -243,595	-52%	-$1.34M	﹤0.01%	1404
2022 Q2	$1.14M	Buy	+468,559	New	+$1.92M	﹤0.01%	1484

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Two Sigma Investments's AVDL Position: Q1 2026 in Review

Two Sigma Investments sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 71,336 shares — an estimated $1.54M sold.

Two Sigma Investments first reported a position in AVDL in Q2 2022 and held it in 9 quarters. The position peaked at $5.42M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Two Sigma Investments reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Two Sigma Investments sold 71,336 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.54M.
Two Sigma Investments first reported a position in Avadel Pharmaceuticals in Q2 2022 and held it in 9 quarters.
Two Sigma Investments's Avadel Pharmaceuticals position peaked at $5.42M in Q2 2023.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.